140 related articles for article (PubMed ID: 9096097)
1. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer.
Hughes OD; Bishop MC; Perkins AC; Frier M; Price MR; Denton G; Smith A; Rutherford R; Schubiger PA
Eur J Nucl Med; 1997 Apr; 24(4):439-43. PubMed ID: 9096097
[TBL] [Abstract][Full Text] [Related]
2. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595.
Hughes OD; Bishop MC; Perkins AC; Wastie ML; Denton G; Price MR; Frier M; Denley H; Rutherford R; Schubiger PA
J Clin Oncol; 2000 Jan; 18(2):363-70. PubMed ID: 10637251
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer.
Murray A; Simms MS; Scholfield DP; Vincent RM; Denton G; Bishop MC; Price MR; Perkins AC
J Nucl Med; 2001 May; 42(5):726-32. PubMed ID: 11337567
[TBL] [Abstract][Full Text] [Related]
4. Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer.
Simms MS; Murray A; Denton G; Scholfield DP; Price MR; Perkins AC; Bishop MC
Urol Res; 2001 Feb; 29(1):13-9. PubMed ID: 11310209
[TBL] [Abstract][Full Text] [Related]
5. Copper-67 as a therapeutic nuclide for radioimmunotherapy.
Novak-Hofer I; Schubiger PA
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):821-30. PubMed ID: 12029558
[TBL] [Abstract][Full Text] [Related]
6. 99mTechnetium-C595 radioimmunoscintigraphy: a potential staging tool for bladder cancer.
Simms MS; Perkins AC; Price MR; Scholfield DP; Bishop MC
BJU Int; 2001 Nov; 88(7):686-91. PubMed ID: 11890238
[TBL] [Abstract][Full Text] [Related]
7. Intravesical administration of radiolabelled tumour-associated monoclonal antibody in bladder cancer.
Syrigos KN; Khawaja M; Krausz T; Williams G; Epenetos AA
Acta Oncol; 1999; 38(3):379-82. PubMed ID: 10380831
[TBL] [Abstract][Full Text] [Related]
8. Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595.
Hughes OD; Perkins AC; Frier M; Wastie ML; Denton G; Price MR; Denley H; Bishop MC
BJU Int; 2001 Jan; 87(1):39-46. PubMed ID: 11121991
[TBL] [Abstract][Full Text] [Related]
9. Immunolocalization of transitional cell carcinoma of the bladder with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody.
Malamitsi J; Zorzos J; Varvarigou AD; Archimandritis S; Dassiou C; Skarlos DV; Dimitriou P; Likourinas M; Zizi A; Proukakis C
Eur J Nucl Med; 1995 Jan; 22(1):25-31. PubMed ID: 7698151
[TBL] [Abstract][Full Text] [Related]
10. Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.
Frier M
Mini Rev Med Chem; 2004 Jan; 4(1):61-8. PubMed ID: 14754444
[TBL] [Abstract][Full Text] [Related]
11. Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.
Hull A; Li Y; Bartholomeusz D; Hsieh W; Tieu W; Pukala TL; Staudacher AH; Bezak E
Cells; 2022 Sep; 11(19):. PubMed ID: 36230945
[TBL] [Abstract][Full Text] [Related]
12. Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy.
Russell PJ; Ho Shon I; Boniface GR; Izard ME; Philips J; Raghavan D; Walker KZ
Urol Res; 1991; 19(4):207-13. PubMed ID: 1926654
[TBL] [Abstract][Full Text] [Related]
13. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
Song EY; Qu CF; Rizvi SM; Raja C; Beretov J; Morgenstern A; Apostolidis C; Bruchertseifer F; Perkins A; Allen BJ
Cancer Biol Ther; 2008 Jan; 7(1):76-80. PubMed ID: 18347423
[TBL] [Abstract][Full Text] [Related]
14. Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas.
Bamias A; Bowles MJ; Krausz T; Williams G; Epenetos AA
Int J Cancer; 1993 Jul; 54(6):899-903. PubMed ID: 8335396
[TBL] [Abstract][Full Text] [Related]
15. Targeted diagnosis and treatment of superficial bladder cancer with monoclonal antibody BDI-1.
Yu L; Gu F; Zhang C; Xie S; Guo Y
Chin Med J (Engl); 1998 May; 111(5):404-7. PubMed ID: 10374347
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
Russell PJ; Plomley J; Shon IH; O'Grady H; Pearce N
Cell Biophys; 1993; 22(1-3):27-47. PubMed ID: 7889541
[TBL] [Abstract][Full Text] [Related]
17. Targeting of bladder cancer with monoclonal antibody NCRC48--a possible approach for intravesical therapy.
Kunkler RB; Bishop MC; Green DJ; Pimm MV; Price MR; Frier M
Br J Urol; 1995 Jul; 76(1):81-6. PubMed ID: 7648066
[TBL] [Abstract][Full Text] [Related]
18. [Radioimmunoimaging of bladder tumor with the intravesical administration of technetium -99m labelled monoclonal antibody].
Li N; Yu L; Zhang C
Zhonghua Wai Ke Za Zhi; 1998 Jan; 36(1):54-6. PubMed ID: 11715544
[TBL] [Abstract][Full Text] [Related]
19. [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
Autenrieth ME; Horn T; Kurtz F; Nguyen K; Morgenstern A; Bruchertseifer F; Schwaiger M; Blechert M; Seidl C; Senekowitsch-Schmidtke R; Gschwend JE; Scheidhauer K
Urologe A; 2017 Jan; 56(1):40-43. PubMed ID: 27885456
[TBL] [Abstract][Full Text] [Related]
20. MUC1 mucin as a tumour marker in bladder cancer.
Simms MS; Hughes OD; Limb M; Price MR; Bishop MC
BJU Int; 1999 Aug; 84(3):350-2. PubMed ID: 10468735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
